Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)				1 Months Ended				3 Months Ended		9 Months Ended		12 Months Ended	20 Months Ended
		Oct. 31, 2021		Jun. 30, 2022	Apr. 30, 2022		May 31, 2018	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Nov. 30, 2020	Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue - current								$ 1,786,000		$ 1,786,000		$ 827,000
Deferred revenue - non-current								31,996,000		31,996,000		19,543,000
Total revenue from collaborations and services								32,825,000	$ 22,211,000	63,711,000	$ 62,927,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services								10,346,000	12,458,000	18,380,000	35,099,000
Commercial product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services								16,259,000	9,753,000	38,807,000	27,828,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services								16,529,000	12,313,000	24,268,000	33,475,000
United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for development of alternative manufacturing processes					$ 700,000
United Therapeutics Corporation | Commercialization and Continuous Improvement Activities
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Funding for capital improvements					2,300,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received														$ 45,000,000.0
Milestone Payment Received													$ 12,500,000
Total anticipated cash flow		$ 463,500,000	[1]		483,200,000	[2]
Deferred revenue								32,200,000		32,200,000
Deferred revenue - current								1,600,000		1,600,000
Deferred revenue - non-current								30,600,000		30,600,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Allocated transaction price including material right		144,500,000			150,200,000
Collaboration and License Agreement | United Therapeutics Corporation | Manufacturing Services | Transaction Price For The Contractual Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flow		64,300,000			71,500,000
Collaboration and License Agreement | United Therapeutics Corporation | Next-Gen R&D Services | Transaction Price For The Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total anticipated cash flow		$ 399,200,000			$ 411,700,000
Collaboration and License Agreement | United Therapeutics Corporation | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional option exercise and development milestone payments to be receive								40,000,000.0		$ 40,000,000.0
Commercial Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Amendment description										The term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA.
Commercial Supply Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services								9,916,000		$ 15,795,000
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services	[3]							9,916,000		15,795,000
Co-Promotion Agreement | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reserve for allowance for credit losses												800,000
Co-Promotion Agreement | Collaborations and services | Vertice Pharma LLC
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services				$ 300,000						325,000	1,147,000
Supply and Distribution Agreement | Commercial product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services										0		$ 0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue								1,600,000		1,600,000
Deferred revenue - current								200,000		200,000
Deferred revenue - non-current								1,400,000		1,400,000
Marketing and distribution agreement date							2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from collaborations and services								$ 37,000	$ 37,000	$ 110,000	$ 110,000

[1] The total anticipated cash flow includes a transaction price of $64.3 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $399.2 million for future supply of Tyvaso DPI over the remaining term of the CSA.

[2] The total anticipated cash flow includes a transaction price of $71.5 million for the contractual obligations under the CSA for the Manufacturing Services and the Next-Gen R&D Services performance obligations and $411.7 million for future supply of Tyvaso DPI over the remaining term of the CSA.

[3] Amount consists of revenue recognized for Manufacturing Services and sales of product to UT for the periods presented.